양극성 장애 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 약제 클래스별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

The global bipolar disorder market was valued at USD 5.1 billion in 2025 and is projected to grow from USD 5.3 billion in 2026 to USD 6.4 billion in 2033, at a CAGR of 2.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. The growth of this market is primarily driven by the increasing prevalence of bipolar disorder and rising government investments to enhance awareness and support advancements in healthcare and research institutions. Furthermore, rapid urbanization and evolving lifestyles have contributed to higher levels of stress and substance abuse, leading to a growing incidence of bipolar disorder. Consequently, the need for effective diagnosis, treatment, and long-term management is driving the market growth.

Bipolar disorder can occur due to various genetic and environmental factors, such as stressful life events, trauma, or emotional abuse, which can lead to the triggering of the condition. Due to changing lifestyles and an increase in stressful work environments, there is a rise in the diagnosis of bipolar disorders. Furthermore, increased awareness of bipolar disorders due to initiatives led by governments and NGOs has increased the number of patients seeking medical help to diagnose and treat their mental health. These initiatives have resulted in a change of perspective and the elimination of stigma related to bipolar disorders, which has further helped in the growth of this market.

Furthermore, substantial investments by leading medical institutes in research and development for bipolar disorder and its treatment have contributed to market growth. Therefore, there is an increase in the number of medicines available to treat bipolar disorders. Due to increased awareness, there is a rise in demand for diagnosis and medication for bipolar disorders. With the increase in the consumption of medicines related to bipolar disorders, companies are increasing the number of drugs in the market by getting approvals from regulatory bodies.

Global Bipolar Disorder Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global bipolar disorder market report based on type, drug class, distribution channel, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

Mood stabilizer

Anticonvulsants

Antipsychotic drugs

Antidepressant drugs

Antianxiety drugs

Other Types

• Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)

Selective serotonin reuptake inhibitor

Serotonin norepinephrine reuptake inhibitor

Tricyclic antidepressant drugs

Monoamine oxidase inhibitors

Benzodiazepines

Beta blockers

Other Drug Classes

• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

• U.S.
• Canada
• Mexico

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• Thailand

Latin America

• Brazil
• Argentina

Middle East and Africa (MEA)

• South Africa
• Saudi Arabia
• UAE
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Bipolar Disorder Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Bipolar Disorder Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Bipolar Disorder Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Bipolar Disorder Market: Type Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Mood Stabilizer
  • 4.3.1. Mood Stabilizer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Anticonvulsants
  • 4.4.1. Anticonvulsant Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Antipsychotic Drugs
  • 4.5.1. Antipsychotic Drugs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Antidepressant Drugs
  • 4.6.1. Antidepressant Drugs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Antianxiety Drugs
  • 4.7.1. Antianxiety Drugs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Other Types
  • 4.8.1. Other Types Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Bipolar Disorder Market: Drug Class Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Bipolar Disorder Market: Drug Class Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Selective Serotonin Reuptake Inhibitor
  • 5.3.1. Selective Serotonin Reuptake Inhibitor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Serotonin Norepinephrine Reuptake Inhibitor
  • 5.4.1. Serotonin Norepinephrine Reuptake Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Tricyclic Antidepressant Drugs
  • 5.5.1. Tricyclic Antidepressant Drugs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Monoamine Oxidase Inhibitors
  • 5.6.1. Monoamine Oxidase Inhibitors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Benzodiazepines
  • 5.7.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Beta Blockers
  • 5.8.1. Beta Blockers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Other Drugs Classes
  • 5.9.1. Other Drugs Classes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Bipolar Disorder Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Bipolar Disorder Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Hospital Pharmacies
  • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Retail Pharmacies
  • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Online Pharmacies
  • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Bipolar Disorder Market: Regional Estimates & Trend Analysis

• 7.1. Bipolar Disorder Market Share, By Region, 2025 & 2033, USD Million
• 7.2. North America
  • 7.2.1. North America Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. China Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Australia
    • 7.4.5.1. Australia Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. South Korea
    • 7.4.6.1. South Korea Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. UAE Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Bipolar Disorder Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Advanced Micro Devices
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. AstraZeneca
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Eli Lilly and Company
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. GSK plc
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Johnson & Johnson Services, Inc
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Pfizer Inc.
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. AbbVie Inc.
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Otsuka Holdings Co., Ltd.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. Bristol-Myers Squibb Company
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Teva Pharmaceutical Industries Ltd.
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives
  • 8.4.11. Sumitomo Pharma America, Inc
    • 8.4.11.1. Participant's Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Recent Developments/ Strategic Initiatives